Volume 7, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2023)
jcbr 2023, 7(2): 5-7 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rasheed F, Karamchedu S, Bagadi V H C, Misbah T, Punjala M G, Nightingale F et al . A clinico-immunohistopathological study of urothelial neoplasms with an expression of HER2/Neu and Ki-67 in malignant lesions presenting to a tertiary centre. jcbr 2023; 7 (2) :5-7
URL: http://jcbr.goums.ac.ir/article-1-422-en.html
URL: http://jcbr.goums.ac.ir/article-1-422-en.html
Fatima Rasheed1 
, Shilpa Karamchedu * 2, Venkata Hari Charan Bagadi1 , Tabassum Misbah1 , Manisha Goud Punjala1 , Florence Nightingale1 , Karamchedu Suresh1
, Shilpa Karamchedu * 2, Venkata Hari Charan Bagadi1 , Tabassum Misbah1 , Manisha Goud Punjala1 , Florence Nightingale1 , Karamchedu Suresh1
1- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India.
2- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India. ,dr.kshilpa@rediffmail.com
2- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India. ,
Abstract: (1414 Views)
Background: HER2/neu is associated with increased tumor grade, and Ki-67 is related to tumor recurrence and stage progression. This study aims to evaluate the clinical profile in patients with urothelial neoplasms and correlate the expression of HER2/neu and Ki-67 in urothelial carcinomas.
Methods: This is a five-year retrospective study from June 2017 to May 2022 with forty cases from the Department of Pathology. A microscopic examination was done to assess the tumor stage and histological grade. Immunohistochemistry was performed with HER2/neu and Ki-67.
Results: 65% (26/40) of the cases were diagnosed as infiltrating urothelial carcinoma, 30% (12) of the cases as low-grade non-invasive urothelial carcinoma, one case as a papillary urothelial neoplasm of low malignant potential (PUNLMP), and one case as urothelial papilloma. 95.5% of infiltrating carcinomas and 84.5% of low-grade non-invasive carcinomas were Ki-67-positive. A significant correlation was observed between the expression of Her-2/neu and Ki-67 and the 2016 World Health Organization (WHO) grading system of urothelial carcinoma. Moderate-to-strong HER2/neu overexpression (2+ or 3+) was observed in only 18% of cases.
Conclusion: The expression of ki-67 increased with an increase in the grade of tumor, which shows its prognostic importance. The relation between Ki-67 expression and the histologic grade of the tumor and the presence of lymphovascular invasion was significant. A significant correlation was observed between the grade of the carcinoma and the immunohistochemical expression of HER2/neu, in which 19.3% of high-grade carcinoma cases showed immunohistochemical expression of the HER2/neu marker. Further studies with a larger population group are required to establish the role of HER2/neu as a prognostic marker.
Methods: This is a five-year retrospective study from June 2017 to May 2022 with forty cases from the Department of Pathology. A microscopic examination was done to assess the tumor stage and histological grade. Immunohistochemistry was performed with HER2/neu and Ki-67.
Results: 65% (26/40) of the cases were diagnosed as infiltrating urothelial carcinoma, 30% (12) of the cases as low-grade non-invasive urothelial carcinoma, one case as a papillary urothelial neoplasm of low malignant potential (PUNLMP), and one case as urothelial papilloma. 95.5% of infiltrating carcinomas and 84.5% of low-grade non-invasive carcinomas were Ki-67-positive. A significant correlation was observed between the expression of Her-2/neu and Ki-67 and the 2016 World Health Organization (WHO) grading system of urothelial carcinoma. Moderate-to-strong HER2/neu overexpression (2+ or 3+) was observed in only 18% of cases.
Conclusion: The expression of ki-67 increased with an increase in the grade of tumor, which shows its prognostic importance. The relation between Ki-67 expression and the histologic grade of the tumor and the presence of lymphovascular invasion was significant. A significant correlation was observed between the grade of the carcinoma and the immunohistochemical expression of HER2/neu, in which 19.3% of high-grade carcinoma cases showed immunohistochemical expression of the HER2/neu marker. Further studies with a larger population group are required to establish the role of HER2/neu as a prognostic marker.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Mushtaq J, Thurairaja R, Nair R. Bladder Cancer. Surgery. 2019;37(9):529-37. [View at Publisher] [DOI] [Google Scholar]
3. Al-Zalabani A, Stewart K, Wesselius A, Schols AMWJ, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: A systematic review of meta-analyses. Eur J Epidemiol. 2016;31(9):811-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Zeegers M, Swaen GMH, Kant I, Goldbohm R, Brandt PAVD. Occupational risk factors for male bladder cancer: results from a population-based case cohort study in the Netherlands. Occup Environ Med. 2001;58(9):590-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Gönül II, Akyürek N, Dursun A, Küpeli B. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumour category and overall patient survival in urothelial tumours of the bladder. Pathol Res Pract. 2008;204(10):707-17. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Madhu K, Ponwang K, Suresh B, Atin S, Rahul Janak S, Sankhwar, et al. Immunohistochemical expession of markars of ki67 and her2 neu and its corelation with clinicopathological parameters of urothelial tumours. International Journal of Current Research. 2016;8(12):43704-08. [View at Publisher] [Google Scholar]
7. Ibrahim BB, Mahmoud SA, Mohamed AA, El Hanbuli HM. Expression of HER2/neu and Ki-67 in Urothelial Carcinoma and their Relation to Clinicopathological Data: An Egyptian Study. Journal of Clinical & Diagnostic Research. 2021;15(3):6-9. [View at Publisher] [DOI] [Google Scholar]
8. Fortuny J, Kogevinas M, Chang-Claude J, 'lez CG, Hours M, KJ; Zeegers MPA, Tan FES, Dorant E, Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk. Cancer. 2000;89(3):630-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Wester K, Sjostrom A, Torre M, Carlsson J, Malmstrom PU. HER-2 a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 2002;41(3):282-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, Muga SD, Salido M. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844-52. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106-19. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Noora Ali J, Hussam Hasson A, Mohammed Subhi K. Her2/ Neu and Ki -67 Immunohistochemical Expression in Transitional Cell Carcinoma of the Urinary Bladder (A Clinicopathological Study). IOSR Journal of Dental and Medical Sciences. 2016;15(2):6-12. [View at Publisher] [DOI] [Google Scholar]
13. Abid A, Sen S, Bandyopadhyay R. Clinicopathological study of urothelial neoplasms in urinary bladder with special reference to expression of Her2/neu and Ki-67 in malignant lesions. Indian J Pathol Oncol. 2021;8(3):369-76. [View at Publisher] [DOI]
14. Badawi MA, El-Sharkawy SL, Abbas NF, Abdel-Aal WE. Image analysis and Ki-67 expression in urothelial dysplasia and carcinoma. J Arab Soc Med Res. 2018;13(2):144-50. [View at Publisher] [DOI] [Google Scholar]
15. Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, et al. Handling and reporting of transurethral resection specimens of the bladder in Europe: A web-based survey by the European Network of Uropathology (ENUP). Histopathology. 2011;58(4):579-85. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Thakur B, Kishore S, Dutta K, Kaushik S, Bhardwaj A. Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder. Indian J Pathol Microbiol. 2017;60(4):505-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Jewett HJ, Blackman SS. Infiltrating Carcinoma of the Bladder: Histologic Pattern and Degree of Cellular Differentiation in 97 Autopsy Cases. J Urol. 1946;56(2):200-10. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Elkady N, Sultan M, Elkhouly E. Evaluation of topoisomerase II, ki-67, and P53 expression in non-muscle-invasive urothelial carcinoma and their clinical significance. Indian J Pathol Microbiol. 2018;61(4):526-31. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Zambelli S, Zanin A, Gaglio A, Zai G, Bosco E, Andrion A, et al. Ki-67 scores and AgNor counts in transitional cell carcinoma of the bladder: apparent lack of prognostic value. Arch Ital Urol Androl. 1993;65(6):665-70. [View at Publisher] [Google Scholar]
20. Suwa Y, Takano Y, Iki M, Asakura T, Noguchi S, Masuda M. Prognostic significance of ki-67 expression in transitional cell bladder carcinoma after radical cystectomy. Pathology. 1997;193(8):551-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Senturk N, Aybek Z, Duzcan E. Ki-67, p53, bcl-2 and bax expression in urothelial carcinomas of urinary bladder. Turk J Pathol. 2010;26(1):25-30. [View at Publisher] [DOI] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).